A Phase I Trial to Determine the Safety, Tolerability, and Maximum Tolerated Dose of Deforolimus in Patients with Advanced Malignancies

PURPOSE: This was a phase I trial to determine the maximum tolerated dose and toxicity of deforolimus (AP23573, MK-8669), an inhibitor of mammalian target of rapamycin (mTOR). The pharmacokinetics, pharmacodynamics, and antineoplastic effects were also studied. EXPERIMENTAL DESIGN: Deforolimus was a...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Hartford, Christine M., Desai, Apurva A., Janisch, Linda, Karrison, Theodore, Rivera, Victor M., Berk, Lori, Loewy, John W., Kindler, Hedy, Stadler, Walter M., Knowles, Heather L., Bedrosian, Camille, Ratain, Mark J.
Formato: Artigo
Idioma:Inglês
Publicado: 2009
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC3147153/
https://ncbi.nlm.nih.gov/pubmed/19228743
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-08-2076
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares